eligibility_summary
Adults 18–70 with R/R CD20 and/or CD30+ lymphoma (DLBCL, PMBCL, TFL, MCL, HGBCL, CLL/SLL, HL) after standard therapy/±transplant, ECOG ≤2, ≥12‑week survival, adequate access/labs/organ function (LVEF ≥45%, O2 >92%), negative pregnancy test. Exclude CNS disease, other malignancy, significant cardiac disease/arrhythmia, uncontrolled infection, HBV/HCV, indwelling drains, recent prohibited therapies/vaccines, active GVHD, autoimmune disease, VTE/MI, marrow failure, pregnancy/lactation, or nonadherence
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06519344 tests intravenous anti‑CD20/CD30 CAR‑T cells—an autologous, gene‑modified cellular immunotherapy (biological). Mechanism: patient T cells are engineered with chimeric antigen receptors that bind CD20 and CD30 on tumor cells, driving T‑cell activation and cytotoxic killing (perforin/granzyme, cytokine release) independent of the native TCR. Single‑center, open‑label, 3+3 dose escalation (3×10^5, 1×10^6, 3×10^6 CAR+ cells/kg) after lymphodepletion. Population: adults with relapsed/refractory CD20/CD30 double‑positive lymphomas, CD20+ B‑cell lymphomas (including post anti‑CD19 CAR‑T relapse), and CD30+ Hodgkin lymphoma (DLBCL, PMBCL, TFL, mantle cell, HGBCL, CLL/SLL, HL). Targets/pathways: CD20 (B‑cell lineage) and CD30 (activated lymphoid/Reed‑Sternberg cells), aiming to eliminate malignant B/CD30+ cells and induce B‑cell aplasia. Outcomes: safety/efficacy, cell kinetics, and cytokine biomarkers.